Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY)-Reference-Cited by-同舟云学术

Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY)

Published:2021-10 Issue:4 Volume:161 Page:1156-1167.e3
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Peyrin-Biroulet Laurent^ORCID,Loftus Edward V.,Colombel Jean-Frédéric,Danese Silvio,Rogers Raquel,Bornstein Jeffrey D.,Chen Jingjing,Schreiber Stefan,Sands Bruce E.,Lirio Richard A.

Funder

Takeda Pharma AG

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference31 articles.

1. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD;Turner;Gastroenterology,2021

2. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: current management;Harbord;J Crohns Colitis,2017

3. ACG Clinical Guideline: ulcerative colitis in adults;Rubin;Am J Gastroenterol,2019

4. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis;Sands;N Engl J Med,2019

5. Adalimumab [prescribing information],2018

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent clinical evidence on nutrition, novel pharmacotherapy, and vaccination in inflammatory bowel diseases;Frontiers in Pharmacology;2024-09-06

2. Challenges in IBD Research 2024: Pragmatic Clinical Research;Inflammatory Bowel Diseases;2024-05-01

3. Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis;Pharmacological Research;2024-04

4. Histological Outcomes and JAK-STAT Signalling in Ulcerative Colitis Patients Treated with Tofacitinib;Journal of Crohn's and Colitis;2024-03-20

5. Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials;Expert Review of Gastroenterology & Hepatology;2024-03-03